N-PEP-12
N-PEP-12 is a proprietary mixture of low-molecular-weight peptides and free amino acids, not a single defined molecule. The 2026 clinical paper describes its study preparation as derived from purified porcine brain proteins.
What is documented about the preparation
| Preparation | Heterogeneous peptide and amino-acid mixture |
| Research models | Neuronal cultures, aged rats and human participants |
| Composition disclosure | Detailed composition and batch analytics were unavailable to the 2026 investigators |
Documents needed to match a preparation
- Manufacturer, label, supplied form and lot number.
- Qualitative and quantitative composition, identity and peptide-content methods.
- Impurity scope, acceptance criteria and lot-specific results.
- Study-product match, handling, storage and stability information.
Product-information inquiry
No matched wholesale SKU or price
The wholesale list has no exact N-PEP-12 match. No form, price tier or availability is published; an inquiry requests product identity and supporting documents, not a purchase or confirmed quotation.
Request the manufacturer and label, supplied form and lot number, composition, identity and content methods, batch results and handling instructions. Published findings do not certify a proposed supply.
What the published studies actually tested
Literature review checked on . Primary studies naming N-PEP-12 were identified in PubMed/Europe PMC and checked against their DOI or journal records. The Windisch and Crook summaries use indexed abstracts; the 2015 animal study and the 2024 and 2026 clinical studies use full texts. This is a focused overview, not an exhaustive systematic review or an experiment conducted by Dr. Peptides.
Windisch et al. (2005). Embryonic chicken cortical neurons were pre-treated from day 1, injured on day 8 with chemical hypoxia, glutamate, calcium overload or cytoskeletal disruption, and measured at 24/48 hours. The abstract reports dose-dependent protection, strongest in mild to moderate lesions. This is an in-vitro model, not a human treatment result. Read the source.
Hutter-Paier et al. (2015). Twenty-seven aged Long Evans rats received daily oral gavage for three months. Some maze outcomes and synaptophysin counts favored N-PEP-12; repeated training produced ceiling effects by month three. This small animal study does not establish human benefit or pharmacokinetics. Read the source.
Crook et al. (2005). A 30-day double-blind placebo-controlled study included 54 adults aged 50 or older with memory loss. The N-PEP-12 group did better on selected memory and clinical measures, but not every secondary test. The small abstract does not support a universal dose or effect size. Read the source.
Mureșanu et al. (2024). In an open-label post-stroke study, 91 of 106 enrolled adults were analyzed; 58 received 90 mg Cebrium daily and 33 were controls without placebo. MoCA favored the intervention at 90 and 360 days, while several secondary tests were null. Attrition, single-centre design and unmeasured rehabilitation limit interpretation. Read the source.
Chira et al. (2026). A randomized placebo-controlled trial assigned 276 adults to placebo, 45 mg or 90 mg daily for 90 days. The conservative model found a group-by-visit interaction but no significant main treatment-arm effect; post-day-90 results were uncontrolled. The paper states that composition, molecular-weight distribution, batch analytics and pharmacokinetics were unavailable. Read the source.
Frequently Asked Questions About N-PEP-12
No. The 2026 study describes a heterogeneous preparation containing low-molecular-weight peptides and free amino acids. The name does not identify one sequence or molecular weight.
Published work includes a small aged-rat study, an older placebo-controlled memory study, an open-label post-stroke study and a 2026 randomized placebo-controlled trial. Their populations, preparations and outcomes differ, so their results should not be pooled into one general efficacy claim.
No general benefit is established. In the 2026 trial, the conservative model found a group-by-visit interaction but no significant main treatment-arm effect. Selected comparisons were exploratory, and there was no concurrent placebo group after day 90.
Do not assume interchangeability. The 2026 paper describes a relationship to Cerebrolysin and identifies MemoProve and Cebrium as marketed names for its study product. Another preparation requires its own manufacturer, composition, form and batch-identity match.
No matched wholesale SKU or price is published. The inquiry form is for product-identity and document questions; it does not confirm a product, price or availability.